美国安进地舒单抗注射液的治疗效果

It is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. RANK receptor signaling promotes osteolysis and tumor growth. Desosumab inhibits tumor growth and reduces bone destruction by binding to RANKL and preventing it from activating RANK on the surface of osteoclasts, osteoclast precursors and osteoclast-like giant cells.

The FDA approved denosumab for the treatment of bone metastases from solid tumors based on the results of three published pivotal clinical trials. A comprehensive analysis of these three studies showed that compared with zoledronic acid, Denosumab prolonged the time to the first adverse bone event (ARE) in patients by 17%, or significantly delayed the median time to the first SRE by 8.2 months (27.6 months vs. 19.4 months). months), Denosumab also extended the time from the first episode to the recurrence of SRE by 18% in the study; in addition, for patients with mild or no pain at the time of study enrollment, Denosumab also significantly prolonged the time to pain exacerbation compared with zoledronic acid.

As one of the world's largest biopharmaceutical companies, Amgen is a leader in the global biopharmaceutical industry. It has strong R&D capabilities and product advantages. It insists on developing in the field of biotechnology for disease treatment. Its main fields include human genome, cancer, neuroscience and small molecule chemistry. According to Medical Travel, the current specification of Amgen in the United States is 120 mg, and the price is only $1,450, which is more suitable for patients to use for a long time. Since the exchange rate has been fluctuating for a long time and the price is unstable, please contact Medical Travel for details.